Possible Role of Fibrinaloid Microclots in Postural Orthostatic Tachycardia Syndrome (POTS): Focus on Long COVID

Journal of Personalized Medicine, Год журнала: 2024, Номер 14(2), С. 170 - 170

Опубликована: Янв. 31, 2024

Postural orthostatic tachycardia syndrome (POTS) is a common accompaniment of variety chronic, inflammatory diseases, including long COVID, as are small, insoluble, 'fibrinaloid' microclots. We here develop the argument, with accompanying evidence, that fibrinaloid microclots, through their ability to block flow blood microcapillaries and thus cause tissue hypoxia, not simply correlated but in fact, by preceding it, may be chief intermediary POTS, which body's exaggerated 'physiological' response hypoxia. Similar reasoning accounts for symptoms bundled under term 'fatigue'. Amyloids known membrane disruptors, when targets nerve membranes, this can explain neurotoxicity hence autonomic nervous system dysfunction contributes POTS. Taken together view, we indicate microclots serve link POTS fatigue COVID manner at once both mechanistic explanatory. This has clear implications treatment such diseases.

Язык: Английский

---

Increased fibrinaloid microclot counts in platelet-poor plasma are associated with Long COVID

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Апрель 5, 2024

Abstract Outcomes following SARS-CoV-2 infection are variable; whilst the majority of patients recover without serious complications, a subset develop prolonged illness termed Long COVID or post-acute sequelae (PASC). The pathophysiology underlying remains unclear but appears to involve multiple mechanisms including persistent inflammation, coagulopathy, autoimmunity, and organ damage. Studies suggest that microclots, also known as fibrinaloids, play role in COVID. In this context, we developed method quantify microclots investigated relationship between microclot counts We show cohort, platelet-poor plasma from samples had higher count compared control groups retained wide distribution counts. Recent COVID-19 infections were seen be associated with than equivalent subsequent time-dependent reduction Our findings could potential biomarker disease and/or treatment target some patients.

Язык: Английский

---

Clinical coding of long COVID in primary care 2020–2023 in a cohort of 19 million adults: an OpenSAFELY analysis

EClinicalMedicine, Год журнала: 2024, Номер 72, С. 102638 - 102638

Опубликована: Май 17, 2024

Язык: Английский

---

Prevalence and risk factors for long COVID in China: a systematic review and meta-analysis of observational studies

Journal of Infection and Public Health, Год журнала: 2025, Номер 18(3), С. 102652 - 102652

Опубликована: Янв. 5, 2025

With the outbreak of COVID-19 in China, a large number patients are at risk long COVID after recovery. The purpose our research is to systematically review existing clinical studies understand current prevalence and related factors China. protocol this systematic was registered on PROSPERO (CRD42024519375). We searched six electronic databases from 1st January 2020-1st March 2024. Literature screening, data extraction, bias assessment were independently carried out by two reviewers. Quality included evaluated AHRQ NOS. meta-analysis performed R software 4.2.3 derive factors. Overall, 50 with 65880 participants included. results showed that (with least one symptom) among approximately % (95 %Confidence Interval (CI) 42-58 %) Although we conducted meta-regression subgroup analysis, heterogeneity study high. But Omicron BA.2 variant had statistically significant effect (P = 0.0004). three most common symptoms fatigue (0.33, 95 %CI 0.28-0.39), cognitive decline (0.30, 0.14-0.46) shortness breath (0.29, 0.15-0.43). Patients severe acute phase (Odds Ratio (OR) 1.57, CI 1.39-1.77), combined 2 comorbidities (OR 1.80, 1.40-2.32), 3 2.13, 1.64-2.77), advanced age 1.02, 1.01-1.04), female 1.58, 1.44-1.73) for prevalence. Current found nearly half may suffering Establishing recovery-support platform regular follow-up would help long-term monitor manage patients, especially those high-risk population.

Язык: Английский

---

Identification of an immunological signature of long COVID syndrome

Frontiers in Immunology, Год журнала: 2025, Номер 15

Опубликована: Янв. 8, 2025

Acute COVID-19 infection causes significant alterations in the innate and adaptive immune systems. While most individuals recover naturally, some develop long COVID (LC) syndrome, marked by persistent or new symptoms weeks to months after SARS-CoV-2 infection. Despite its prevalence, there are no clinical tests distinguish LC patients from those fully recovered. Understanding immunological basis of is essential for improving diagnostic treatment approaches. We performed deep immunophenotyping functional assays examine profiles patients, with active COVID-19, recovered healthy donors. This analysis assessed both features, identifying potential biomarkers syndrome. A Binomial Generalized Linear Model (BGLM) was used pinpoint features characterizing LC. exhibited depletion cell subsets, including plasmacytoid conventional dendritic cells, classical, non-classical, intermediate monocytes, monocyte-derived inflammatory cells. Elevated basal inflammation observed compared whose were closer donors individuals. However, displayed alterations, reduced T subsets (CD4, CD8, Tregs) switched memory B similar patients. Through BGLM, a unique signature identified, featuring CD8 gd cells low proliferative capacity diminished expression activation homing receptors. The findings highlight associated characterized dysregulation. recovery comparable Recovered individuals, deficits populations evident, differentiating full recovery. These provide insights into pathogenesis may support development tools targeted therapies.

Язык: Английский

---